Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

119.80EUR
11:58am GMT
Change (% chg)

€-0.20 (-0.17%)
Prev Close
€120.00
Open
€119.00
Day's High
€120.25
Day's Low
€119.00
Volume
39,296
Avg. Vol
121,388
52-wk High
€129.85
52-wk Low
€76.58

Chart for

About

Ipsen SA is a France-based pharmaceutical company. The Company is focused on various therapeutic areas, including onocology, endocrinology, neurosciences and primary care. Its onocology portfolio includes Somatuline, Decapeptyl, Hexvix and Cabometyx. Its endocrinology portfolio includes Increlex and NutropinAq. Its primary care... (more)

Overall

Beta: 0.75
Market Cap(Mil.): €9,633.51
Shares Outstanding(Mil.): 83.66
Dividend: 0.85
Yield (%): 0.74

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

French pharma group Ipsen sees more asset purchases, U.S. growth

PARIS French pharma company Ipsen expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros ($1.25 billion) for asset purchases, its chief executive said.

15 Feb 2018

French pharma group Ipsen sees more asset purchases, U.S. growth

PARIS French pharma company Ipsen expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros (888.29 million pounds) for asset purchases, its chief executive said.

15 Feb 2018

BRIEF-Ipsen FY IFRS Operating Income Up At 397.2 Million Euros

* IPSEN DELIVERS STRONG 2017 RESULTS WITH 21.1%1 SALES GROWTH AND CORE OPERATING MARGIN INCREASE OF 3.4 POINTS AND EXPECTS SIGNIFICANT FURTHER GROWTH IN SALES AND MARGIN IN 2018

15 Feb 2018

BRIEF-Ipsen Appoints Sotirios G. Stergiopoulos As Chief Medical Officer‍​

* DR SOTIRIOS G. STERGIOPOULOS APPOINTED AS IPSEN CHIEF MEDICAL OFFICER‍​ Further company coverage: (Gdynia Newsroom)

26 Jan 2018

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

16 Jan 2018

BRIEF-Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America

* IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

12 Jan 2018

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​

29 Nov 2017

BRIEF-Ipsen ‍reports Q3 2017 group sales growth of 22.6%​

* Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Oct 2017

BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib

* IPSEN ANNOUNCES THAT PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

16 Oct 2017

BRIEF-Ipsen receives approval from European Commission for Xermelo

* Ipsen receives approval from European Commission for Xermelo® (Telotristat Ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

19 Sep 2017

Earnings vs. Estimates